Get 40% Off
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did.Read how

Biden to announce $1.5 billion to fight U.S. opioid crisis

Published 09/23/2022, 05:09 AM
Updated 09/23/2022, 05:36 PM
© Reuters. FILE PHOTO: A Cataldo Ambulance medic holds used doses of naloxone after medics revived a man in his 40's who was found unresponsive from an opioid overdose in the Boston suburb of Salem, Massachusetts, U.S., August 9, 2017. REUTERS/Brian Snyder

By Ahmed Aboulenein

WASHINGTON (Reuters) - U.S. President Joe Biden will announce on Friday nearly $1.5 billion to fund access to medications for opioid overdoses, sanctions against traffickers, and increased funding for law enforcement, the White House said.

The Biden administration is keen to show it is taking action on a worsening nationwide opioid crisis, which according to U.S. Centers for Disease Control and Prevention data fueled more than 107,000 drug overdose deaths in 2021, a nearly 15% increase from the previous year.

"Our nation is facing 108,000 overdose deaths in just 12 months. That's one life lost every five minutes around the clock," said Dr. Rahul Gupta, director of National Drug Control Policy at the White House.

"The Biden-Harris administration is announcing several key investments and actions to reduce overdose deaths, ensure public health and law enforcement officials on the front lines have the resources they need, support people in recovery, and finally beat this epidemic," Gupta told reporters on a press call.

Biden will announce nearly $1.5 billion in grants from the U.S. Department of Health and Human Services to states, tribal lands and territories, said Miriam Delphin-Rittmon, assistant secretary for mental health and substance use.

The funds will go toward treating substance-use disorders and removing barriers to key tools like naloxone, a medication that can reverse opioid overdoses, Delphin-Rittmon said.

The grants will also fund recovery support services, overdose education efforts, peer support specialists in emergency departments, and care for stimulant use and misuse disorders including cocaine and methamphetamine, she added.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The U.S. Food and Drug Administration will release new guidance to ease restrictions on naloxone, said Gupta.

Currently, there are legal barriers limiting access to naloxone in some states, and in others it is not always available to those most at risk of an overdose because patients are more likely to receive a prescription if they had a prior diagnosis of opioid misuse or dependence along with an overdose than if they have had those diagnoses without an overdose.

Biden is also announcing an additional $12 million in funding for law enforcement in areas suffering the worst of drug trafficking, on top of $275 million announced in April, and sanctions on individuals and groups involved with drug cartels.

Latest comments

government ignorance created the problem followed by the usual solution. lay the blame on companies we can fine billions. resulting in candy colored fentanyl from China ***our children. good job. can't wait to see the next round of short slighted legislation
A crisis he started with $1.9 trillion
Close the border dementia Joe!
seems a little short compared to the Ukraine handouts.
what a nonsense
We need to fix the corrupt FDA and build the *******wall.
What a joke. Close the border! Worst president ever.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.